Does the media favor SRRK or VIR?

In the previous week, Scholar Rock had 8 more articles in the media than Vir Biotechnology. MarketBeat recorded 11 mentions for Scholar Rock and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.24 beat Scholar Rock's score of 0.61 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CGON or VIR?

In the previous week, CG Oncology had 3 more articles in the media than Vir Biotechnology. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Vir Biotechnology. CG Oncology's average media sentiment score of 1.35 beat Vir Biotechnology's score of 1.24 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or VIR?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Vir Biotechnology. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.24 beat Mirum Pharmaceuticals' score of 0.73 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ERAS or VIR?

In the previous week, Erasca had 6 more articles in the media than Vir Biotechnology. MarketBeat recorded 9 mentions for Erasca and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.24 beat Erasca's score of 1.01 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VIR or TVTX?

In the previous week, Travere Therapeutics had 6 more articles in the media than Vir Biotechnology. MarketBeat recorded 9 mentions for Travere Therapeutics and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.24 beat Travere Therapeutics' score of 1.02 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vir Biotechnology (VIR) Competitors

$10.62 +0.04 (+0.38%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$10.54 -0.07 (-0.71%)

As of 09/11/2026 07:30 PM Eastern

Compare

VIR vs. SRRK, CGON, MIRM, ERAS, and TVTX

Should you buy Vir Biotechnology stock or one of its competitors? Vir Biotechnology's main competitors and comparable companies include Scholar Rock (SRRK), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), Erasca (ERAS), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vir Biotechnology compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Scholar Rock has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

Scholar Rock currently has a consensus price target of $58.77, indicating a potential upside of 6.06%. Vir Biotechnology has a consensus price target of $21.57, indicating a potential upside of 103.12%. Given Vir Biotechnology's higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Scholar Rock has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Scholar Rock has higher earnings, but lower revenue than Vir Biotechnology. Scholar Rock is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Vir Biotechnology	$302.59M	5.94	-$437.99M	-$1.86	N/A

In the previous week, Scholar Rock had 8 more articles in the media than Vir Biotechnology. MarketBeat recorded 11 mentions for Scholar Rock and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.24 beat Scholar Rock's score of 0.61 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Scholar Rock and Vir Biotechnology tied by winning 8 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

CG Oncology presently has a consensus price target of $87.78, indicating a potential upside of 21.32%. Vir Biotechnology has a consensus price target of $21.57, indicating a potential upside of 103.12%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

CG Oncology has higher earnings, but lower revenue than Vir Biotechnology. CG Oncology is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$6.23M	1,029.72	-$160.99M	-$2.69	N/A
Vir Biotechnology	$302.59M	5.94	-$437.99M	-$1.86	N/A

In the previous week, CG Oncology had 3 more articles in the media than Vir Biotechnology. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Vir Biotechnology. CG Oncology's average media sentiment score of 1.35 beat Vir Biotechnology's score of 1.24 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vir Biotechnology has a net margin of -638.88% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

CG Oncology has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market.

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vir Biotechnology beats CG Oncology on 10 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Mirum Pharmaceuticals has a net margin of -139.18% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Mirum Pharmaceuticals presently has a consensus target price of $137.31, indicating a potential upside of 39.80%. Vir Biotechnology has a consensus target price of $21.57, indicating a potential upside of 103.12%. Given Vir Biotechnology's higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Mirum Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$618.07M	10.32	-$23.36M	-$14.55	N/A
Vir Biotechnology	$302.59M	5.94	-$437.99M	-$1.86	N/A

65.3% of Vir Biotechnology shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Mirum Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Vir Biotechnology. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.24 beat Mirum Pharmaceuticals' score of 0.73 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats Vir Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Erasca?

Erasca (NASDAQ:ERAS) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Erasca has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Erasca presently has a consensus price target of $22.09, suggesting a potential upside of 39.11%. Vir Biotechnology has a consensus price target of $21.57, suggesting a potential upside of 103.12%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

67.8% of Erasca shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Erasca had 6 more articles in the media than Vir Biotechnology. MarketBeat recorded 9 mentions for Erasca and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.24 beat Erasca's score of 1.01 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

Erasca has higher earnings, but lower revenue than Vir Biotechnology. Erasca is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Vir Biotechnology	$302.59M	5.94	-$437.99M	-$1.86	N/A

Summary

Vir Biotechnology beats Erasca on 9 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Travere Therapeutics?

Vir Biotechnology (NASDAQ:VIR) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Vir Biotechnology presently has a consensus price target of $21.57, indicating a potential upside of 103.12%. Travere Therapeutics has a consensus price target of $68.00, indicating a potential upside of 2.77%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, research analysts plainly believe Vir Biotechnology is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Travere Therapeutics had 6 more articles in the media than Vir Biotechnology. MarketBeat recorded 9 mentions for Travere Therapeutics and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.24 beat Travere Therapeutics' score of 1.02 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.3% of Vir Biotechnology shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vir Biotechnology has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Travere Therapeutics has a net margin of -7.35% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Travere Therapeutics has higher revenue and earnings than Vir Biotechnology. Travere Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$302.59M	5.94	-$437.99M	-$1.86	N/A
Travere Therapeutics	$591.33M	10.55	-$25.55M	-$0.46	N/A

Summary

Travere Therapeutics beats Vir Biotechnology on 9 of the 17 factors compared between the two stocks.

Get Vir Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIR vs. The Competition

Export

Metric	Vir Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.79B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-5.71	14.25	275.24	25.29
Price / Sales	5.94	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	1.93	15.12	10.33	6.20
Net Income	-$437.99M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-6.76%	-4.34%	-3.32%	-2.35%
1 Month Performance	18.53%	-0.02%	-0.41%	-2.77%
1 Year Performance	112.40%	40.64%	19.21%	7.63%

Vir Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIR Vir Biotechnology	1.8584 of 5 stars	$10.62 +0.4%	$21.57 +103.1%	+103.1%	$1.79B	$302.59M	N/A	367	Positive News
SRRK Scholar Rock	1.801 of 5 stars	$56.80 -1.7%	$58.77 +3.5%	+74.0%	$7.04B	N/A	N/A	140	News Coverage Analyst Forecast
CGON CG Oncology	3.1677 of 5 stars	$75.16 +1.1%	$83.18 +10.7%	+118.2%	$6.59B	$4.04M	N/A	61	Positive News Options Volume
MIRM Mirum Pharmaceuticals	2.8182 of 5 stars	$98.05 +0.6%	$137.31 +40.0%	+29.3%	$6.33B	$521.31M	N/A	140	Gap Down
ERAS Erasca	2.427 of 5 stars	$17.88 -0.8%	$22.09 +23.6%	+886.3%	$6.31B	N/A	N/A	120	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIR) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Competitors

VIR vs. SRRK, CGON, MIRM, ERAS, and TVTX

How does Vir Biotechnology compare to Scholar Rock?

Summary

How does Vir Biotechnology compare to CG Oncology?

Summary

How does Vir Biotechnology compare to Mirum Pharmaceuticals?

Summary

How does Vir Biotechnology compare to Erasca?

Summary

How does Vir Biotechnology compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Competitors

VIR vs. SRRK, CGON, MIRM, ERAS, and TVTX

How does Vir Biotechnology compare to Scholar Rock?

Which has more volatility & risk, SRRK or VIR?

Do analysts recommend SRRK or VIR?

Is SRRK or VIR more profitable?

Which has preferable valuation & earnings, SRRK or VIR?

Does the media favor SRRK or VIR?

Do insiders & institutionals have more ownership in SRRK or VIR?

Summary

How does Vir Biotechnology compare to CG Oncology?

Do analysts prefer CGON or VIR?

Which has preferable earnings & valuation, CGON or VIR?

Does the media favor CGON or VIR?

Is CGON or VIR more profitable?

Which has more risk & volatility, CGON or VIR?

Do institutionals & insiders have more ownership in CGON or VIR?

Summary

How does Vir Biotechnology compare to Mirum Pharmaceuticals?

Is MIRM or VIR more profitable?

Do analysts recommend MIRM or VIR?

Which has higher earnings & valuation, MIRM or VIR?

Do insiders & institutionals have more ownership in MIRM or VIR?

Which has more volatility and risk, MIRM or VIR?

Does the media favor MIRM or VIR?

Summary

How does Vir Biotechnology compare to Erasca?

Is ERAS or VIR more profitable?

Do analysts rate ERAS or VIR?

Do insiders and institutionals have more ownership in ERAS or VIR?

Does the media favor ERAS or VIR?

Which has more volatility & risk, ERAS or VIR?

Which has better valuation & earnings, ERAS or VIR?

Summary

How does Vir Biotechnology compare to Travere Therapeutics?

Do analysts recommend VIR or TVTX?

Does the media refer more to VIR or TVTX?

Do institutionals & insiders believe in VIR or TVTX?

Which has more volatility & risk, VIR or TVTX?

Is VIR or TVTX more profitable?

Which has preferable valuation & earnings, VIR or TVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools